Isofol Medical AB (publ) appointed Jenny Sundqvist as Chief Commercial Officer (CCO) as of January 1, 2022. Jenny is currently the Head of Commercial and Strategy Development at Isofol. Former CCO, Tony Gustavsson, leaves Isofol for a new international assignment in a global pharmaceutical group. In her new role as CCO, Jenny Sundqvist will be part of Isofol's senior management team and will be responsible for implementing the commercial preparations that were intensified in 2021. During the year, Isofol strengthened its commercial resources internally in the company as well as engaged additional external resources with the ambition that market approval of arfolitixorin will be possible during the second half of 2023, given a positive outcome from the ongoing phase III study.